Tandem Diabetes Care Toekomstige groei

Future criteriumcontroles 1/6

Tandem Diabetes Care zal naar verwachting groeien in winst en omzet met respectievelijk 49.9% en 10.3% per jaar. De winst per aandeel zal naar verwachting groeien met 51.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.2% zijn.

Belangrijke informatie

49.9%

Groei van de winst

51.3%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	10.3%
Toekomstig rendement op eigen vermogen	6.2%
Dekking van analisten	Good
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 04

Recent updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Nov 16

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 04

Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Jul 12

Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Jun 18

Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

May 29

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

May 10

A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

May 04

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Mar 26

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Mar 08

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Feb 22

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jan 14

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Dec 27

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Nov 12

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Oct 06

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Sep 17

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Aug 08

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jul 03

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Jun 13

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

May 06

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Jan 04

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Oct 15

Tandem Diabetes Care: Overpriced, Underdelivering

Sep 22

An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Sep 10

Tandem Diabetes stock falls 10% on disappointing Q2 result

Aug 03

Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed

Jul 21

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

Jul 08

Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital

Jun 20

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price

May 30

Winst- en omzetgroeiprognoses

NasdaqGM:TNDM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,117	-47	30	83	18
12/31/2025	1,007	-81	-3	72	21
12/31/2024	907	-109	-5	-49	21
9/30/2024	854	-127	-37	6	N/A
6/30/2024	796	-136	-64	-20	N/A
3/31/2024	770	-141	-67	-21	N/A
12/31/2023	748	-223	-83	-32	N/A
9/30/2023	771	-208	-49	-19	N/A
6/30/2023	790	-224	-41	5	N/A
3/31/2023	795	-204	-33	18	N/A
12/31/2022	801	-95	8	50	N/A
9/30/2022	791	-68	21	64	N/A
6/30/2022	766	-13	50	74	N/A
3/31/2022	738	6	74	96	N/A
12/31/2021	703	16	88	111	N/A
9/30/2021	661	22	85	107	N/A
6/30/2021	605	7	62	87	N/A
3/31/2021	542	-25	45	74	N/A
12/31/2020	499	-34	-8	25	N/A
9/30/2020	439	-49	-6	29	N/A
6/30/2020	410	-42	5	37	N/A
3/31/2020	394	-17	1	25	N/A
12/31/2019	362	-25	22	42	N/A
9/30/2019	330	-24	23	37	N/A
6/30/2019	282	-55	0	10	N/A
3/31/2019	223	-113	-4	0	N/A
12/31/2018	184	-123	-11	-8	N/A
9/30/2018	148	-138	-38	-34	N/A
6/30/2018	129	-119	N/A	-50	N/A
3/31/2018	116	-82	N/A	-58	N/A
12/31/2017	108	-73	N/A	-66	N/A
9/30/2017	96	-76	N/A	-68	N/A
6/30/2017	82	-90	N/A	-67	N/A
3/31/2017	83	-87	N/A	-66	N/A
12/31/2016	84	-83	N/A	-61	N/A
9/30/2016	84	-81	N/A	-58	N/A
6/30/2016	88	-70	N/A	-54	N/A
3/31/2016	81	-72	N/A	-59	N/A
12/31/2015	73	-72	N/A	-59	N/A
9/30/2015	62	-79	N/A	-62	N/A
6/30/2015	59	-79	N/A	-61	N/A
3/31/2015	54	-79	N/A	-60	N/A
12/31/2014	50	-80	N/A	-61	N/A
9/30/2014	42	-85	N/A	-61	N/A
6/30/2014	36	-78	N/A	-58	N/A
3/31/2014	32	-74	N/A	-56	N/A
12/31/2013	29	-63	N/A	-48	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TNDM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TNDM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TNDM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van TNDM ( 10.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van TNDM ( 10.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen TNDM zal naar verwachting over 3 jaar laag zijn ( 6.2 %).

Tandem Diabetes Care Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Price target increased by 7.8% to US$37.36

Consensus EPS estimates fall by 31%

Price target increased by 10.0% to US$31.67

Price target decreased by 26% to US$29.73

Price target decreased by 7.3% to US$37.80

Recent updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Tandem Diabetes Care, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Tandem Diabetes Care, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 3000E Value Index

Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024

Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

President exercised options and sold US$503k worth of stock

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.8% to US$37.36

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Consensus EPS estimates fall by 31%

Now 21% undervalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Price target increased by 10.0% to US$31.67

Now 23% undervalued

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 26% to US$29.73

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Price target decreased by 7.3% to US$37.80

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Now 23% undervalued after recent price drop

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Price target decreased by 8.8% to US$46.07

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Independent Director recently bought US$295k worth of stock

Executive VP recently bought US$99k worth of stock

Consensus EPS estimates fall by 127%

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

First quarter 2023 earnings: EPS misses analyst expectations

Executive VP & COO notifies of intention to sell stock

Price target decreased by 8.1% to US$54.38

Full year 2022 earnings: EPS misses analyst expectations

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Executive VP & COO notifies of intention to sell stock

Consensus forecasts updated

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

High number of new directors

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop